Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Adilson A. Faccio
Observed names:
A Faccio,
A. Faccio,
Adilson Faccio
Observed institution:
Universidade de São Paulo
ORCID:
0000-0003-0032-5107
Observed ORCID:
0000-0003-0032-5107
OpenAlex ID:
A5048766362
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
2024
·
B. Sangro
, S.L. Chan
, et al.
·
Annals of Oncology
·
362
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC
2025
·
Lorenza Rimassa
, Stephen L. Chan
, et al.
·
Journal of Hepatology
·
175
Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer: The Phase III PACIFIC-2 Study
2025
·
Jeffrey D. Bradley
, Shunichi Sugawara
, et al.
·
Journal of Clinical Oncology
·
77
Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study
2025
·
Hani M. Babiker
, Vincent Picozzi
, et al.
·
Journal of Clinical Oncology
·
48
PDF
947MO Five-year overall survival (OS) and OS by tumour response measures from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
2024
·
L. Rimassa
, S.L. Chan
, et al.
·
Annals of Oncology
·
25
PDF
127O Five-year overall survival (OS) and OS by baseline liver function from the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
2024
·
M. Kudo
, L. Rimassa
, et al.
·
Annals of Oncology
·
6
PDF
A Rare Presentation of Biphasic Pulmonary Blastoma
2002
·
Simone G. Ramos
, Gisele G. Rezende
, et al.
·
Archives of Pathology & Laboratory Medicine
·
6
ACVR2B polymorphism, Adiponectin, and GDF-15 levels as biomarkers for cachexia in gastrointestinal cancer
2024
·
Laura de Martin Coletti
, Gabriela Gonzalez Segura
, et al.
·
Scientific Reports
·
3
Subsequent anticancer therapy analysis of the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
2025
·
F van Bömmel
, G K Abou-Alfa
, et al.
·
Zeitschrift für Gastroenterologie
·
1
404: Five-year Overall Survival (os) and Os by Baseline Liver Function From the Phase 3 Himalaya Study of Tremelimumab (t) Plus Durvalumab (d) in Unresectable Hepatocellular Carcinoma (uhcc)
2025
·
Masatoshi Kudo
, Lorenza Rimassa
, et al.
·
Gastroenterology
·
1
Patients with gastrointestinal cancer are more susceptible to unintentional weight loss after chemotherapy treatment
2023
·
Gabriela Gonzalez Segura
, Laura Martin Coletti
, et al.
·
Brazilian Journal of Development
·
1
PDF
Plain language summary of five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (liver cancer)
2026
·
Lorenza Rimassa
, Stephen L. Chan
, et al.
·
Figshare
Plain language summary of five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (liver cancer)
2026
·
Lorenza Rimassa
, Stephen L. Chan
, et al.
·
Future Oncology
PDF
33 - Análisis De Los Tratamientos Subsiguientes Antineoplásicos Del Estudio De Fase 3 Himalaya: Tremelimumab Más Durvalumab En El Carcinoma Hepatocelular Avanzado O Irresecable
2026
·
Bruno Sangro
, Ghassan K. Abou-Alfa
, et al.
·
Gastroenterología y Hepatología
Five-year overall survival (OS) and OS by baseline liver function from the Phase 3 HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
2025
·
T Wirth
, M Kudo
, et al.
·
Zeitschrift für Gastroenterologie
Su1751: FIVE-YEAR OVERALL SURVIVAL (OS) AND OS BY TUMOR RESPONSE MEASURES FROM THE PHASE 3 HIMALAYA STUDY OF TREMELIMUMAB PLUS DURVALUMAB IN UNRESECTABLE HEPATOCELLULAR CARCINOMA (UHCC)
2025
·
Lorenza Rimassa
, Stephen L. Chan
, et al.
·
Gastroenterology
Five-year overall survival (OS) and OS by tumour response measures from the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
2025
·
Najib Ben Khaled
, Lorenza Rimassa
, et al.
·
Zeitschrift für Gastroenterologie
Avaliação da perda de peso em pacientes oncológicos tratados com diferentes protocolos quimioterápicos
2022
·
Laura de Martin Coletti
, Gabriela Gonzalez Segura
, et al.
·
Brazilian Journal of Case Reports
PDF
Biphasic pulmonaru blastoma: a rare case with immunohistochemical study
2001
·
Simone G. Ramos
, Gizelle Gouvea Rezende
, et al.
·
Jornal Brasileiro de Patologia e Medicina Laboratorial
Show more works
View as search
Works count:
19
Citation count:
703
H-index:
6
I10-index:
5
Year
Topic
Type
